18432695. Biosensors in Human Gut Organoids simplified abstract (The General Hospital Corporation)

Biosensors in Human Gut Organoids

Organization Name

The General Hospital Corporation

Inventor(s)

Alessio Fasano of Boston MA (US)

Timothy K. Lu of Cambridge MA (US)

Stefania Senger of Melrose MA (US)

Maria Eugenia Inda of Cambridge MA (US)

Biosensors in Human Gut Organoids - A simplified explanation of the abstract

This abstract first appeared for US patent application 18432695 titled 'Biosensors in Human Gut Organoids

Simplified Explanation

The patent application describes ex vivo monolayer models of human intestinal epithelia that express sensors, and methods of using them to evaluate the effects of test compounds on the human gut.

• These models are designed to mimic the human intestinal epithelium in a laboratory setting.
• The sensors incorporated into the models allow for real-time monitoring of the effects of test compounds on the intestinal epithelium.
• The methods described in the patent application provide a way to assess the impact of various compounds on the human gut without the need for invasive procedures.

Potential Applications

The technology could be used in drug development to assess the effects of new compounds on the human gut before clinical trials. It could also be utilized in personalized medicine to tailor treatments based on individual gut responses.

Problems Solved

This technology addresses the need for more accurate and efficient methods of evaluating the effects of compounds on the human gut. Traditional methods may be invasive or time-consuming, whereas these ex vivo models provide a non-invasive and real-time approach.

Benefits

The benefits of this technology include improved understanding of how compounds affect the human gut, leading to more effective and personalized treatments. It also offers a more ethical alternative to animal testing in gut-related research.

Potential Commercial Applications

Potential commercial applications of this technology could include partnerships with pharmaceutical companies for drug development, as well as collaborations with healthcare providers for personalized medicine applications.

Possible Prior Art

One possible prior art could be the use of animal models to study the effects of compounds on the gut. However, these models may not accurately reflect human physiology, making the ex vivo human intestinal epithelia models a more relevant and reliable alternative.

How does this technology compare to in vivo studies on the human gut?

This article does not directly address the comparison between ex vivo models and in vivo studies on the human gut. Further research may be needed to determine the advantages and limitations of each approach.

What are the potential limitations of using ex vivo models for studying the human gut?

The article does not discuss the potential limitations of using ex vivo models for studying the human gut. It would be important to consider factors such as the lifespan of the models and their ability to accurately replicate the complexity of the human gut.

Original Abstract Submitted

Ex vivo monolayer models of human interstinal epithelia that express sensors, and methods of use thereof for evaluation of the effects of test compounds on the human gut.